<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162992</url>
  </required_header>
  <id_info>
    <org_study_id>ICOR-2014-01</org_study_id>
    <nct_id>NCT02162992</nct_id>
  </id_info>
  <brief_title>Systemic Lupus Erythematous and Heart Conduction Disorders</brief_title>
  <official_title>Repolarization Disorders and Heart Conduction Disorders in Patients With Systemic Lupus Erythematous</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Connective tissue diseases have been related to heart conduction disorders. The anti-Ro/SSA
      antibodies are thought to have a pathogenic role, and they most prevalent in systemic lupus
      erythematous (SLE). The aim of this study is to evaluate the relationship between SLE,
      arrhythmias and its serologic profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed a cross-sectional study for an observational analysis. The target population will
      be the group of SLE patients visited the service of Rheumatology hospitals in Catalonia
      (Spain).

      The criteria for subjects selection to participate in our project are:

      1 . Inclusion criteria: patients with SLE according to established diagnostic criteria in
      1997 2. Exclusion criteria:

        -  Presence of cardiac: Ischemic heart disease or congenital or acquired structural heart
           disease (hypertrophic cardiomyopathy, idiopathic dilated cardiomyopathy, valve disease
           with clinical significance).

        -  Background heart surgery or cardiac ablation procedures.

        -  Background in other pathological processes has been described affecting cardiac
           conduction tissue: Steinert's disease, Lyme disease, Chagas' disease with heart
           involvement or hypothyroidism.

      The selection of patients and controls are done through a sampling of consecutive patients
      seen in our outpatient rheumatology center to achieve the sample size. This has been fixed in
      two subgroups: 100 patients with SLE and positive for anti-Ro (with positivity for anti-Ro
      only 52 or positivity for anti-Ro and anti-Ro 52 60) and 50 patients (controls ) with SLE and
      negative for anti-Ro (anti-Ro52 and anti-Ro 60).

      As defined as primary variables, the study of cardiac conduction disorders will be done
      through the analysis of resting electrocardiogram (ECG) and a 24-hour Holter.

      Other descriptive variables are listed below:

        -  Collection of general medical history of patients, with emphasis on Rheumatology and
           cardiac involvement.

        -  Check the current medication.

        -  Height and weight.

        -  Physical examination.

        -  12-lead resting ECG with analysis of rate base, as well as the duration of the PR
           interval, QRS and QT. Analysis of the presence of intraventricular conduction disorders
           and the presence of ectopic beats.

        -  Record 24-hour Holter Presence and number of ventricular ectopic beats, classification
           of events according to the Lown's criteria. Presence of significant pauses (RR interval&gt;
           2000mseg). Measurement of corrected QT (QTc).

        -  Presence of autonomic dysfunction parameters: time domain parameters such as the mean RR
           interval, standard deviation of all normal RR intervals (SDNN), the root of the mean
           difference between successive adjacent normal RR intervals (RMSSD ) and the percentage
           of adjacent intervals over 50mseg (PNN50)

        -  Echocardiography to rule out structural heart disease: Analysis of ventricular diameters
           and systolic and diastolic function, presence of significant valve disease, pulmonary
           systolic pressure, pericardial effusion and other congenital or acquired structural
           heart disease.

        -  Analysis with serologic immune profile, determining the degree of organic involvement by
           SLE
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile</measure>
    <time_frame>24 hours</time_frame>
    <description>Conduction disorders will be evaluated by 12-lead ECG recordings an 24-hour Holter recordings. Measurements will include PR intervals (in msec), QRS duration (in msec) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QT and Corrected QT Intervals</measure>
    <time_frame>24 hours</time_frame>
    <description>Ventricular repolarization will be evaluated by 12-lead ECG recordings an 24-hour Holter recordings. Measurements will include QT and corrected QT intervals, and the presence of ventricular arrhythmia. Corrected QT (QTc) intervals will be obtained by measuring the QT interval (QTm) and the previous RR interval, following the Bazett formula (QTc=QTm divided by the square root of previous RR interval in seconds). A comparison will be made between the anti-Ro60 antibody positive patients and the anti-Ro60 antibody negative patients.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">151</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <condition>Atrioventricular Block</condition>
  <condition>Sudden Death</condition>
  <arm_group>
    <arm_group_label>SLE and Anti-Ro antibodies Group</arm_group_label>
    <description>Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLE without Anti-Ro antibodies Group</arm_group_label>
    <description>Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Observational</description>
    <arm_group_label>SLE and Anti-Ro antibodies Group</arm_group_label>
    <arm_group_label>SLE without Anti-Ro antibodies Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with SLE visited in the rheumatology outpatient's area.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with SLE diagnosis, according to SLE diagnostic criteria.

        Exclusion Criteria:

          -  Patients with previous cardiac diseases (ischemic heart disease, hypertrophic
             cardiomyopathy, dilated cardiomyopathy, valvular heart disease)

          -  Clinical history of heart surgery or ablation procedures

          -  Clinical history of other conditions that affect heart conduction:

               -  Steinert Disease

               -  Lyme Disease

               -  Chagas Disease

               -  Hypothyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Villuendas</last_name>
    <role>Principal Investigator</role>
    <affiliation>GTIPUH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Germans Trias i Pujol University Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Lazzerini PE, Capecchi PL, Laghi-Pasini F. Anti-Ro/SSA antibodies and cardiac arrhythmias in the adult: facts and hypotheses. Scand J Immunol. 2010 Sep;72(3):213-22. doi: 10.1111/j.1365-3083.2010.02428.x. Review.</citation>
    <PMID>20696018</PMID>
  </reference>
  <reference>
    <citation>Chameides L, Truex RC, Vetter V, Rashkind WJ, Galioto FM Jr, Noonan JA. Association of maternal systemic lupus erythematosus with congenital complete heart block. N Engl J Med. 1977 Dec 1;297(22):1204-7.</citation>
    <PMID>917056</PMID>
  </reference>
  <reference>
    <citation>Seferović PM, Ristić AD, Maksimović R, Simeunović DS, Ristić GG, Radovanović G, Seferović D, Maisch B, Matucci-Cerinic M. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology (Oxford). 2006 Oct;45 Suppl 4:iv39-42. Review.</citation>
    <PMID>16980722</PMID>
  </reference>
  <reference>
    <citation>Edwards CS, Mootoo R, Bhanji A. High grade heart block in association with SLE. Ann Rheum Dis. 2004 May;63(5):606.</citation>
    <PMID>15082501</PMID>
  </reference>
  <reference>
    <citation>Costedoat-Chalumeau N, Georgin-Lavialle S, Amoura Z, Piette JC. Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block. Lupus. 2005;14(9):660-4. Review.</citation>
    <PMID>16218462</PMID>
  </reference>
  <reference>
    <citation>Santos-Pardo I, Martínez-Morillo M, Villuendas R, Bayes-Genis A. Anti-Ro antibodies and reversible atrioventricular block. N Engl J Med. 2013 Jun 13;368(24):2335-7. doi: 10.1056/NEJMc1300484.</citation>
    <PMID>23758256</PMID>
  </reference>
  <reference>
    <citation>Behan WM, Behan PO, Gairns J. Cardiac damage in polymyositis associated with antibodies to tissue ribonucleoproteins. Br Heart J. 1987 Feb;57(2):176-80.</citation>
    <PMID>3493020</PMID>
  </reference>
  <reference>
    <citation>Logar D, Kveder T, Rozman B, Dobovisek J. Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis. 1990 Aug;49(8):627-9.</citation>
    <PMID>2396870</PMID>
  </reference>
  <reference>
    <citation>O'Neill TW, Mahmoud A, Tooke A, Thomas RD, Maddison PJ. Is there a relationship between subclinical myocardial abnormalities, conduction defects and Ro/La antibodies in adults with systemic lupus erythematosus? Clin Exp Rheumatol. 1993 Jul-Aug;11(4):409-12.</citation>
    <PMID>8403587</PMID>
  </reference>
  <reference>
    <citation>Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR. Adult heart block is associated with disease activity in primary Sjögren's syndrome. Scand J Rheumatol. 2005 Sep-Oct;34(5):383-6.</citation>
    <PMID>16234186</PMID>
  </reference>
  <reference>
    <citation>Costa M, Gameiro Silva MB, Silva JA, Skare TL. Anti-RO anti-LA anti-RNP antibodies and eletrocardiogram's PR interval in adult patients with systemic lupus erythematosus. Acta Reumatol Port. 2008 Apr-Jun;33(2):173-6.</citation>
    <PMID>18604183</PMID>
  </reference>
  <reference>
    <citation>Lazzerini PE, Capecchi PL, Guideri F, Acampa M, Galeazzi M, Laghi Pasini F. Connective tissue diseases and cardiac rhythm disorders: an overview. Autoimmun Rev. 2006 May;5(5):306-13. Epub 2005 Dec 9. Review.</citation>
    <PMID>16782554</PMID>
  </reference>
  <reference>
    <citation>Lazzerini PE, Capecchi PL, Acampa M, Morozzi G, Bellisai F, Bacarelli MR, Dragoni S, Fineschi I, Simpatico A, Galeazzi M, Laghi-Pasini F. Anti-Ro/SSA-associated corrected QT interval prolongation in adults: the role of antibody level and specificity. Arthritis Care Res (Hoboken). 2011 Oct;63(10):1463-70. doi: 10.1002/acr.20540.</citation>
    <PMID>21739618</PMID>
  </reference>
  <reference>
    <citation>Villuendas R, Olivé A, Juncà G, Salvador I, Martínez-Morillo M, Santos-Pardo I, Pereferrer D, Zamora E, Bayes-Genis A. Autoimmunity and atrioventricular block of unknown etiology in adults: the role of anti-Ro/SSA antibodies. J Am Coll Cardiol. 2014 Apr 8;63(13):1335-1336. doi: 10.1016/j.jacc.2013.10.086. Epub 2014 Jan 30.</citation>
    <PMID>24486277</PMID>
  </reference>
  <reference>
    <citation>Gordon PA, Rosenthal E, Khamashta MA, Hughes GR. Absence of conduction defects in the electrocardiograms [correction of echocardiograms] of mothers with children with congenital complete heart block. J Rheumatol. 2001 Feb;28(2):366-9. Erratum in: J Rheumatol 2001 May;28(5):1200.</citation>
    <PMID>11246679</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <results_first_submitted>September 4, 2019</results_first_submitted>
  <results_first_submitted_qc>October 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2019</results_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Germans Trias i Pujol Hospital</investigator_affiliation>
    <investigator_full_name>Roger Villuendas Sabaté</investigator_full_name>
    <investigator_title>Coordinator of the Electrophysiology and Cardiac Pacing Unit</investigator_title>
  </responsible_party>
  <keyword>Antibodies, Antinuclear</keyword>
  <keyword>SS-A antigen</keyword>
  <keyword>Lupus Erythematosus, Systemic</keyword>
  <keyword>Atrioventricular Block</keyword>
  <keyword>Sudden death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrioventricular Block</mesh_term>
    <mesh_term>Cardiac Conduction System Disease</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02162992/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SLE and Anti-Ro Antibodies Group</title>
          <description>Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
No intervention: Observational</description>
        </group>
        <group group_id="P2">
          <title>SLE Without Anti-Ro Antibodies Group</title>
          <description>Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
No intervention: Observational</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SLE and Anti-Ro Antibodies Group</title>
          <description>Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
No intervention: Observational</description>
        </group>
        <group group_id="B2">
          <title>SLE Without Anti-Ro Antibodies Group</title>
          <description>Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
No intervention: Observational</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.14" spread="11.75"/>
                    <measurement group_id="B2" value="45.24" spread="12.81"/>
                    <measurement group_id="B3" value="44.49" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Latin-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>North-African</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile</title>
        <description>Conduction disorders will be evaluated by 12-lead ECG recordings an 24-hour Holter recordings. Measurements will include PR intervals (in msec), QRS duration (in msec) .</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SLE and Anti-Ro Antibodies Group</title>
            <description>Patients with SLE visited in the rheumatology outpatient's area with positivity to Anti-Ro antibodies. No intervention (only observational)
No intervention: Observational</description>
          </group>
          <group group_id="O2">
            <title>SLE Without Anti-Ro Antibodies Group</title>
            <description>Patients with SLE visited in the rheumatology outpatient's area with negativity to Anti-Ro antibodies. No intervention (only observational)
No intervention: Observational</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile</title>
          <description>Conduction disorders will be evaluated by 12-lead ECG recordings an 24-hour Holter recordings. Measurements will include PR intervals (in msec), QRS duration (in msec) .</description>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QRS duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.22" spread="8.5"/>
                    <measurement group_id="O2" value="91.41" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.68" spread="21.1"/>
                    <measurement group_id="O2" value="146.72" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QT and Corrected QT Intervals</title>
        <description>Ventricular repolarization will be evaluated by 12-lead ECG recordings an 24-hour Holter recordings. Measurements will include QT and corrected QT intervals, and the presence of ventricular arrhythmia. Corrected QT (QTc) intervals will be obtained by measuring the QT interval (QTm) and the previous RR interval, following the Bazett formula (QTc=QTm divided by the square root of previous RR interval in seconds). A comparison will be made between the anti-Ro60 antibody positive patients and the anti-Ro60 antibody negative patients.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SLE and Anti-Ro Antibodies Group</title>
            <description>Patients with SLE visited in the rheumatology outpatient's area with positivity to Anti-Ro antibodies. No intervention (only observational)
No intervention: Observational</description>
          </group>
          <group group_id="O2">
            <title>SLE Without Anti-Ro Antibodies Group</title>
            <description>Patients with SLE visited in the rheumatology outpatient's area with negativity to Anti-Ro antibodies. No intervention (only observational)
No intervention: Observational</description>
          </group>
        </group_list>
        <measure>
          <title>QT and Corrected QT Intervals</title>
          <description>Ventricular repolarization will be evaluated by 12-lead ECG recordings an 24-hour Holter recordings. Measurements will include QT and corrected QT intervals, and the presence of ventricular arrhythmia. Corrected QT (QTc) intervals will be obtained by measuring the QT interval (QTm) and the previous RR interval, following the Bazett formula (QTc=QTm divided by the square root of previous RR interval in seconds). A comparison will be made between the anti-Ro60 antibody positive patients and the anti-Ro60 antibody negative patients.</description>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Corrected QT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="420.74" spread="24.3"/>
                    <measurement group_id="O2" value="421.33" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT dispersion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.25" spread="7.8"/>
                    <measurement group_id="O2" value="6.81" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SLE and Anti-Ro Antibodies Group</title>
          <description>Patients with SLE visited in the rheumatology outpatient's area with positivity to Anti-Ro antibodies. No intervention (only observational)
No intervention: Observational</description>
        </group>
        <group group_id="E2">
          <title>SLE Without Anti-Ro Antibodies Group</title>
          <description>Patients with SLE visited in the rheumatology outpatient's area with negativity to Anti-Ro antibodies. No intervention (only observational)
No intervention: Observational</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Roger Villuendas</name_or_title>
      <organization>H. Germans Trias i Pujol</organization>
      <phone>+34 4978398</phone>
      <email>rogervilluendas@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

